Isotopia Announces: Aseptic Manufacturing Plant Relocates from Soreq to Modiin
Modiin, Israel – Isotopia Molecular Imaging, a global leader in innovative radiopharmaceuticals for diagnostics and therapy, today announced the relocation of its aseptic manufacturing plant from the Soreq Nuclear Research Center to a new, state-of-the-art facility in Modiin. The move marks a significant milestone in the company’s expansion strategy and further demonstrates its commitment to meeting the growing global demand for radiopharmaceuticals and sterile injectable preparations.
Isotopia Announces: Aseptic Manufacturing Plant Relocates from Soreq to Modiin
Modiin, Israel – Isotopia Molecular Imaging, a global leader in innovative radiopharmaceuticals for diagnostics and therapy, today announced the relocation of its aseptic manufacturing plant from the Soreq Nuclear Research Center to a new, state-of-the-art facility in Modiin. The move marks a significant milestone in the company’s expansion strategy and further demonstrates its commitment to meeting the growing global demand for radiopharmaceuticals and sterile injectable preparations.
World-Class Manufacturing Facility
The new Modiin facility spans over 2,000 square meters of advanced manufacturing space, designed specifically for aseptic pharmaceutical production. This significant investment in cutting-edge technology and infrastructure positions Isotopia at the forefront of sterile manufacturing capabilities and Contract Manufacturing Organization (CMO) services.
Advanced Filling Line Technology
Isotopia is planning to install a state-of-the-art filling line from a leading market manufacturer, featuring integrated systems that ensure the highest levels of sterility and quality control. The entire production line will operate within an advanced isolator system, representing the gold standard in aseptic manufacturing.
Operational Excellence and Future Approvals
The facility is designed to meet and exceed international regulatory standards.
Isotopia plans to pursue GMP (Good Manufacturing Practices) and FDA approvals, ensuring compliance with the strictest global pharmaceutical manufacturing standards.
Advanced isolator technology and automated systems enable shorter production times and significantly higher capacity compared to traditional aseptic methods. This efficiency allows Isotopia to better serve the growing demand for radiopharmaceuticals while maintaining the highest quality standards.
Commitment to Injectable Preparations
Isotopia will continue producing injectable preparations, which are essential for delivering life-saving drugs, and cold kits for the radiopharmaceutical industry.
Aseptic manufacturing is particularly critical for radiopharmaceuticals, biologics, and other heat-sensitive compounds that are unsuited to undergo terminal sterilization. The new facility’s advanced capabilities ensure these products maintain efficacy while meeting the highest safety standards.
Strategic Location Advantages
Modiin offers significant advantages for pharmaceutical manufacturing and distribution.
Its industrial and technology park provides modern infrastructure, reliable utilities, and a business-friendly ecosystem that supports innovation and growth, making it an ideal location for pharmaceutical operations.
Looking Forward
“This step represents more than a change of address – it reflects Isotopia’s commitment to innovation, quality, and growth in the global radiopharmaceutical market” says Tzachi Levy Site GM. “The new facility positions the company to expand our aseptic capabilities and CMO services, offering comprehensive manufacturing solutions to pharmaceutical companies worldwide.”
As global demand for radiopharmaceuticals and sterile injectables continues to rise, particularly in theranostics and precision medicine, Isotopia’s investment in advanced manufacturing ensures it remains at the forefront of this critical industry. The relocation to Modiin marks a new chapter in Isotopia’s journey as a global leader in radiopharmaceutical innovation, reinforcing its mission to transform cancer diagnosis and therapy through the power of nuclear medicine.
Strategic Growth and Market Expansion
As Isotopia continues its unprecedented growth. The company is actively seeking partnerships with organizations worldwide that can benefit from its vast expertise in radiopharmaceutical manufacturing and supply chain management, while upholding the highest standards of quality and regulatory compliance.
With demand for aseptic manufacturing services rising—especially for complex formulations, cold kits, and sterile injectables, Isotopia is ready to collaborate and drive innovation together with partners that share our values.
